

Fig. S1 Diagram of this study
CF, cisplatin plus 5-fluorouracil; DCF, docetaxel, cisplatin plus 5-fluorouracil; ESCC, esophageal squamous cell cancer; and NAC, neoadjuvant chemotherapy.




Table S1.
Characteristics of 186 esophageal cancer patients.

Characteristics	Total (n=186)
Median follow-up duration, months (range)	35.8 (1-65)
Median age, years (range)	66.5 (42-80)
Sex, n (%)	
Male	145 (78.0)
Female	41 (22.0)
Location, n (%)	
Upper	27 (14.5)
Middle	70 (37.6)
Lower	89 (47.8)
Regimen of NAC, n (%)	
DCF	96 (51.6)
CF	90 (48.4)
ypT, n (%)	
ypT0	25 (13.4)
ypTis	29 (15.6)
ypT1	43 (23.1)
ypT2	22 (11.8)
ypT3	66 (35.5)
ypT4	1 (0.5)
ypN, n (%)	
ypN0	94 (50.5)
ypN1	52 (28.0)
ypN2	23 (12.4)
ypN3	17 (9.1)
ypM, n (%)	
ypM0	175 (94.1)
ypM1	11 (5.9)
ypStage, n (%)	
ypStage 0	43 (23.1)
ypStage I	21 (11.3)
ypStage II	48 (25.8)
ypStage III	50 (26.9)
ypStage IV	24 (12.9)
Lymphovascular invasion, n (%)	
Absent	89 (47.8)
Present	97 (52.2)
Tumor regression grade, n (%)	
0	27 (14.5)
1a	51 (27.4)
1b	57 (30.6)
2	26 (14.0)
3	25 (13.5)

Abbreviations: CF, cisplatin plus 5-fluorouracil; DCF, docetaxel, cisplatin plus 5-fluorouracil; NAC, neoadjuvant chemotherapy; TRG, tumor regression grade

Fig. S2 Kaplan-Meier curves on the recurrence-free survival (RFS) according to the ypT stage (a), ypN stage (b), ypStage (c), and tumor regression grade (TRG) (d)




Fig. S3 Kaplan-Meier curves on the recurrence-free survival (RFS) for patients with ypT3 stage

• ypT3 Patients

